In vivo data clearly demonstrated that the TGFβ-trap architecture enhanced anti-tumor capability of EGFRvIII-specific CAR-Ts in a TGFβ context and prolonged survival of GBM-bearing mice. This evidence concerns the gene TGFB1 and glioblastoma.